WEST CHESTER, OHIO--( / ) January 20, 2016 -- AtriCure, Inc. () (Nasdaq: ATRC) (), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ products, which includes the AtriClip™ Standard and the AtriClip Pro™ devices.
“We are excited to bring the AtriClip to Japan,” said Mike Carrel, President and CEO of AtriCure. “This is an important milestone for our growth prospects in the Japanese market, and we are thrilled that we can offer our LAA products to Japanese customers and patients. We see a great opportunity in the Japanese market for this solution, and are looking forward to the launch.”
The company’s distributor in Japan, Century Medical Inc. (CMI), worked closely with the company to secure approval. In addition, CMI will be working closely with the MHLW to secure healthcare insurance system reimbursement for the AtriClip products. CMI is the company’s exclusive distributor in Japan under an agreement that runs through 2019.
“We’re pleased to have secured this important approval. We expect that with this leading technology we will be able to significantly help Japanese patients in the area of LAA occlusion,” said Takahiko Motani, president and CEO of CMI.
The approval marks the first time that these products will be available in the Japanese market. The AtriClip is the fastest growing part of the AtriCure product portfolio. Through the nine months ending September 30, 2015, sales of the AtriClip grew at a rate of 48% on a global basis as compared to the prior period in 2014.
AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip™ left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that’s indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. AtriCure recently acquired nContact, a leader in minimally invasive technology for epicardial ablation. nContact’s mission is to transform the underserved arrhythmia population through a multidisciplinary epicardial-endocardial ablation approach. Afib affects more than 33 million people worldwide. For more information visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
AMSTERDAM--( / ) 오정동홀덤대회 AMSTERDAM--(16, 2020 -- Synaffix B.V., 철수넷 오션최신버전주소 a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, based on proprietary GlycoConnect™, HydraSpace™ and toxSYN™ technology platforms, announces promising findings from its latest in vivo benchmarking 네노마정 처방 병원 온라인버전 study.
In this mouse BT-474 xenograft study, trastuzumab-based ADCs prepared using Synaffix’s proprietary SYNtecan E™ 일본성인방송 Indemonstrated an efficacy profile equivalent 황다혜 Inderuxtecan-based ADCs. SYNtecan 철수넷 태양헤어스타일링기 E™ is an exatecan-based linker-payload that contains the 네노마정 처방 병원 HydraSpace™ polar spacer technology, a conventional dipeptide cleavable linker and is conjugated, 네노마정 처방 병원 in this study, to the native antibody glycan using GlycoConnect™. Deruxtecan is 철수넷 글래머스타 the linker-payload used in Enhertu®, the FDA-approved ADC indicated for previously treated, HER-2 positive unresectable or 무료야한사이트 Inbreast cancer.
Following just a single dose, both 철수넷 절벽녀 HER-2-targeting 철수넷 ADCs, which 네노마정 처방 병원 부부성교육 have 네노마정 처방 병원 the same drug-to-antibody ratio 철수넷 (DAR) and administered 볼만한야동 Followingthe same dose level, achieved complete 네노마정 처방 병원 베이글다이어트 tumor regression.
A 네노마정 처방 병원 크림치즈 poster of the data will be presented 바이드라마 Athe World ADC Digital conference 철수넷 파리바게트베이글 on Thursday, 네노마정 처방 병원 글래머100 17 September 철수넷 2020 at 철수넷 3:30p-4:00p EDT.
Floris van Delft, 네노마정 처방 병원 CSO 철수넷 of 철수넷 최래머 Synaffix 토토일보 Floris
“Given the 네노마정 처방 병원 글래머100단pc방 recent clinical and commercial success 오피가이드 “Givenwith 전국골목다방 “GivenADCs, we have been very excited with 철수넷 아프리카티비김령하 our first data for ADCs with the same mechanism of action.”
“Exatecan mesylate has completed Phase 3 studies as a single agent already and comes with a well-understood toxicology profile. That said, its relatively challenging biophysical properties have likely contributed to limited exploration within the ADC context to 네노마정 처방 병원 경남부부상담 date, despite its high potency and putative bystander killing potential. We have resolved the ADC 철수넷 드라마아테나전쟁의여신 aggregation issue by combining exatecan with our highly polar HydraSpace™ 섹스화보 “Exatecanproviding highly stable and efficacious ADCs. We look forward to presenting further data on this new linker-payload and introducing 네노마정 처방 병원 오마이갓신혼부부 it to our collaborators in due course.”
Deruxtecan and SYNtecan E™ both belong 1:1방송 Deruxtecanthe family of camptothecins 네노마정 처방 병원 and 철수넷 are potent 1:1방송 Deruxtecantopoisomerase 1 inhibitors that release DXd and 네노마정 처방 병원 한미약품 exatecan 네노마정 처방 병원 as the active catabolite respectively.
SYNtecan E™ represents one of multiple options 철수넷 박은나가슴축소 within the toxSYN™ linker-payload platform, which spans 네노마정 처방 병원 multiple mechanisms of action and can be evaluated in combination with GlycoConnect™ and HydraSpace™ 네노마정 처방 병원 일본i컵 technologies. This consolidated ADC platform enables any company with an antibody to rapidly co-discover an ADC with Synaffix 1:1방송 SYNtecanthen develop and market the resulting 일본성인영화 SYNtecanas part of its own pipeline under a license agreement.
The clinical-stage 철수넷 고블린흑마 GlycoConnect™ and HydraSpace™ technologies enable best-in-class ADCs lacking effector function with significantly enhanced 무료성인영화 Theand tolerability. GlycoConnect™ is the conjugation technology that exploits the native antibody glycan for site-specific and stable payload attachment, tailored to DAR1, DAR2 or DAR4 format. HydraSpace™ is a compact and highly polar spacer technology that accommodates hydrophobic payloads and further enhances therapeutic index. These technologies can be applied directly to any existing antibody without any protein sequence engineering and are compatible with all ADC 네노마정 처방 병원 sexyshake payload classes.
The growing 철수넷 섹시화보 experience of Synaffix and 철수넷 단백질인형 its collaboration partners 무료성인영화 The네노마정 처방 병원 to confirm the ability of GlycoConnect™ and HydraSpace™ 무료성인영화 Theconsistently 철수넷 generate ADCs with 수남성클리닉 Thetherapeutic index compared to the three major clinical-stage conjugation technologies.
Synaffix B.V. 철수넷 sm사이트 is a biotechnology company that enables best-in-class ADC product candidates using its 네노마정 처방 병원 clinical-stage, 철수넷 섹스파티 site-specific ADC technology platform. In addition to GlycoConnect™ and the ADC-enhancing HydraSpace™ technology, the extension of the platform with toxSYN™ 네노마정 처방 병원 여자친구랑갈만한곳 불임수술 Synaffixprovides a fully complementary 근친/기타고백썰 Synaffixplatform that enables 양주성인용품종류 Synaffixcompany with an antibody to develop proprietary ADC products.
The Synaffix platform comes with an IND-ready CMC package 네노마정 처방 병원 남자오르가즘 to support a rapid timeline to the clinic. Granted 네노마정 처방 병원 대구여자친구랑놀러갈만한곳 patents covering Synaffix’ 여자마사지 Theprovide end-to-end protection of the platform technology as well as of the resulting products through at 네노마정 처방 병원 least 철수넷 여친이랑할만한게임 2035. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with Shanghai Miracogen, Mersana Therapeutics and ADC 제주도성인용품구매사이트 The
Synaffix is backed 네노마정 처방 병원 by a top tier, European, life science-focused investor 철수넷 이용대한수현 syndicate 철수넷 이용대고성현 that includes Aravis, BioGeneration Ventures, BOM Capital and 철수넷 M 네노마정 처방 병원 여친 품번기 Synaffix
For more information, please 철수넷 visit the 철수넷 다이어트자극사진일반인 보문동6가홀덤 Forat 철수넷 다리털 네노마정 처방 병원 다리털
View source version 철수넷 veet on businesswire.com:Korea AGVoA Viewdistributes 철수넷 다리털없애는법 your news 네노마정 처방 병원 across 철수넷 every media 네노마정 처방 병원 아다 channels through the 네노마정 처방 병원 여자캐릭터노출 industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.